Literature DB >> 10557341

Axon pathology in Parkinson's disease and Lewy body dementia hippocampus contains alpha-, beta-, and gamma-synuclein.

J E Galvin1, K Uryu, V M Lee, J Q Trojanowski.   

Abstract

Pathogenic alpha-synuclein (alphaS) gene mutations occur in rare familial Parkinson's disease (PD) kindreds, and wild-type alphaS is a major component of Lewy bodies (LBs) in sporadic PD, dementia with LBs (DLB), and the LB variant of Alzheimer's disease, but beta-synuclein (betaS) and gamma-synuclein (gammaS) have not yet been implicated in neurological disorders. Here we show that in PD and DLB, but not normal brains, antibodies to alphaS and betaS reveal novel presynaptic axon terminal pathology in the hippocampal dentate, hilar, and CA2/3 regions, whereas antibodies to gammaS detect previously unrecognized axonal spheroid-like lesions in the hippocampal dentate molecular layer. The aggregation of other synaptic proteins and synaptic vesicle-like structures in the alphaS- and betaS-labeled hilar dystrophic neurites suggests that synaptic dysfunction may result from these lesions. Our findings broaden the concept of neurodegenerative "synucleinopathies" by implicating betaS and gammaS, in addition to alphaS, in the onset/progression of PD and DLB.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10557341      PMCID: PMC23968          DOI: 10.1073/pnas.96.23.13450

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  40 in total

Review 1.  Pathobiology of the Lewy body.

Authors:  J E Galvin; V M Lee; M L Schmidt; P H Tu; T Iwatsubo; J Q Trojanowski
Journal:  Adv Neurol       Date:  1999

Review 2.  Fatal attractions: abnormal protein aggregation and neuron death in Parkinson's disease and Lewy body dementia.

Authors:  J Q Trojanowski; M Goedert; T Iwatsubo; V M Lee
Journal:  Cell Death Differ       Date:  1998-10       Impact factor: 15.828

3.  Antibodies to alpha-synuclein detect Lewy bodies in many Down's syndrome brains with Alzheimer's disease.

Authors:  C F Lippa; M L Schmidt; V M Lee; J Q Trojanowski
Journal:  Ann Neurol       Date:  1999-03       Impact factor: 10.422

4.  Synapsin I in nerve terminals: selective association with small synaptic vesicles.

Authors:  F Navone; P Greengard; P De Camilli
Journal:  Science       Date:  1984-12-07       Impact factor: 47.728

5.  Hippocampal degeneration differentiates diffuse Lewy body disease (DLBD) from Alzheimer's disease: light and electron microscopic immunocytochemistry of CA2-3 neurites specific to DLBD.

Authors:  D W Dickson; D Ruan; H Crystal; M H Mark; P Davies; Y Kress; S H Yen
Journal:  Neurology       Date:  1991-09       Impact factor: 9.910

6.  Identification and localization of synaptophysin, an integral membrane glycoprotein of Mr 38,000 characteristic of presynaptic vesicles.

Authors:  B Wiedenmann; W W Franke
Journal:  Cell       Date:  1985-07       Impact factor: 41.582

7.  Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble alpha-synuclein.

Authors:  P H Tu; J E Galvin; M Baba; B Giasson; T Tomita; S Leight; S Nakajo; T Iwatsubo; J Q Trojanowski; V M Lee
Journal:  Ann Neurol       Date:  1998-09       Impact factor: 10.422

8.  Ubiquitin and microtubule-associated protein tau immunoreactivity each define distinct structures with differing distributions and solubility properties in Alzheimer brain.

Authors:  G Shaw; V Chau
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

9.  Abnormal distribution of the non-Abeta component of Alzheimer's disease amyloid precursor/alpha-synuclein in Lewy body disease as revealed by proteinase K and formic acid pretreatment.

Authors:  A Takeda; M Hashimoto; M Mallory; M Sundsumo; L Hansen; A Sisk; E Masliah
Journal:  Lab Invest       Date:  1998-09       Impact factor: 5.662

10.  Standardization of various applications of methacrylate embedding and silver methenamine for light and electron microscopy immunocytochemistry.

Authors:  E M Rodríguez; R Yulis; B Peruzzo; G Alvial; R Andrade
Journal:  Histochemistry       Date:  1984
View more
  151 in total

1.  Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology.

Authors:  J E Galvin; B Giasson; H I Hurtig; V M Lee; J Q Trojanowski
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

2.  Biochemical and morphological consequences of human α-synuclein expression in a mouse α-synuclein null background.

Authors:  Kavita Prasad; Elizabeth Tarasewicz; Pamela A Ohman Strickland; Michael O'Neill; Stephen N Mitchell; Kalpana Merchant; Samnang Tep; Kathryn Hilton; Akash Datwani; Manuel Buttini; Sarah Mueller-Steiner; Eric K Richfield
Journal:  Eur J Neurosci       Date:  2011-01-28       Impact factor: 3.386

3.  Lipid rafts mediate the synaptic localization of alpha-synuclein.

Authors:  Doris L Fortin; Matthew D Troyer; Ken Nakamura; Shin-ichiro Kubo; Malcolm D Anthony; Robert H Edwards
Journal:  J Neurosci       Date:  2004-07-28       Impact factor: 6.167

Review 4.  Axon degeneration in Parkinson's disease.

Authors:  Robert E Burke; Karen O'Malley
Journal:  Exp Neurol       Date:  2012-01-18       Impact factor: 5.330

5.  Suppression, disaggregation, and modulation of γ-Synuclein fibrillation pathway by green tea polyphenol EGCG.

Authors:  Sneha Roy; Rajiv Bhat
Journal:  Protein Sci       Date:  2018-12-20       Impact factor: 6.725

Review 6.  α-Synuclein aggregation modulation: an emerging approach for the treatment of Parkinson's disease.

Authors:  Sushil K Singh; Aloke Dutta; Gyan Modi
Journal:  Future Med Chem       Date:  2017-06-20       Impact factor: 3.808

7.  Secondary structure and dynamics of micelle bound beta- and gamma-synuclein.

Authors:  Yoon-Hui Sung; David Eliezer
Journal:  Protein Sci       Date:  2006-04-05       Impact factor: 6.725

8.  A pH-dependent switch promotes β-synuclein fibril formation via glutamate residues.

Authors:  Gina M Moriarty; Michael P Olson; Tamr B Atieh; Maria K Janowska; Sagar D Khare; Jean Baum
Journal:  J Biol Chem       Date:  2017-07-14       Impact factor: 5.157

Review 9.  Current perspective of mitochondrial biology in Parkinson's disease.

Authors:  Navneet Ammal Kaidery; Bobby Thomas
Journal:  Neurochem Int       Date:  2018-03-14       Impact factor: 3.921

10.  Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV alpha-synucleinopathy.

Authors:  Chee Yeun Chung; James B Koprich; Hasan Siddiqi; Ole Isacson
Journal:  J Neurosci       Date:  2009-03-18       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.